Analysis of the efficacy of an adjuvant-based inactivated pandemic H5N1 influenza virus vaccine

This study showed that the candidate vaccine is safe and elicits an antigen-dose-dependent serum antibody response. In summary, we determined the optimum antigen dose in a Kazfluvac® adjuvant formulation required for induction of heightened immunogenicity and protective efficacy to mitigate H5N1 disease in experimental animals, suggesting its readiness for clinical studies in humans.
Source: Archives of Virology - Category: Virology Source Type: research